Gel4Med

What Gel4Med does

Gel4Med is a commercial-stage biomaterials company that develops peptide-based therapeutic matrices for wound care, surgical reconstruction, and regenerative medicine. The company was founded out of Harvard Innovation Labs and is headquartered in Brighton, Massachusetts, with an R&D laboratory co-located at the University of Massachusetts Lowell's M2D2 facility. It currently commercializes two FDA 510(k)-cleared products — G4Derm Plus, a flowable biomimetic matrix for managing complex wounds including diabetic, pressure, venous, and arterial ulcers as well as surgical and burn wounds; and Suprello, a peptide-based surgical wound matrix targeting high-risk surgical cases with antibacterial protection against multidrug-resistant organisms. Both products are built on Gel4Med's proprietary, patented Smart Materials Platform (SMP), which uses self-assembling peptide technology to form 3D scaffolds that mimic the human extracellular matrix. The SMP architecture enables tunable properties including adaptable form factors (flowable, spray, film), customizable biodegradation rates, biomechanical tunability, stimuli responsiveness, and antimicrobial capability without donor-source biological variability or resistance-development risk typical of conventional antibiotics.

Gel4Med sells its products in the United States through a hybrid go-to-market model: direct enterprise field sales to hospital systems and wound care clinics, dedicated government sales to VA and DoD medical facilities (via a federal contractor with DUNS, CAGE, and NAICS registrations), and distribution partnerships — most notably with Spartan Medical for the VA/DoD channel and with Summit Products Group alongside MiMEDX Group for acute-care and surgical-suite hospital-system access. The company holds a unique CMS HCPCS Level II reimbursement code (A2037) for G4Derm Plus, enabling standardized insurance billing. Pricing is not publicly disclosed and is structured as unit-based per-SKU sales (e.g., 2ml prefilled syringes), with separate ordering channels for government and non-government buyers. Beyond commercial products, the company maintains an active R&D pipeline — including a spinal cord injury cell therapy candidate developed with the University of Miami's Miami Project to Cure Paralysis under a $1.75M CDMRP/DoD grant — that leverages the SMP into higher-value regenerative medicine applications.

The company is funded primarily through non-dilutive grants from federal and state sources, including NIH (SBIR Phase II and Commercial Readiness Pilot), the Department of Defense (CDMRP), MassVentures, the Massachusetts Life Sciences Center, and the National Science Foundation, with strategic support from Harvard Innovation Labs and Breakout Labs. Gel4Med holds registered trademarks for G4Derm Plus and Suprello and patents covering its Smart Materials Platform. Headcount is reported in the 11-50 range, led by Co-Founder and CEO Manav Mehta, PhD, with an advisory board that includes the former Chief Scientific Officer of Integra Life Sciences.

Name

Gel4Med

Legal name

Gel4Med, Inc.

Website

https://gelformed.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Gel4Med is a commercial-stage biomaterials company that develops FDA 510(k)-cleared self-assembling peptide matrices (G4Derm Plus and Suprello) for complex wound care and surgical reconstruction, serving hospitals, wound care clinics, and VA/DoD medical facilities in the United States.

Ownership category

akta.pro rank

Product category

Wound Care Biomaterials

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

akta.pro secondary industries

Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB), Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film) (HLAHALAA), Wound Closure & Securement (Sutures, Staples, Tissue Adhesives, Skin Closure Strips) (HLAHALAD), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

Keywords

• Wound care biomaterials
• Peptide-based scaffolds
• Regenerative medicine devices
• Surgical wound matrices
• Biomimetic tissue engineering

Headquarters

HQ city

Allston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Product Sales - G4Derm Plus and Suprello: Commercial-stage company generating revenue through sales of FDA 510(k)-cleared wound care products G4Derm Plus and Suprello. Products sold as medical devices through government and non-government channels.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Core offering

Gel4Med develops and commercializes FDA 510(k)-cleared, peptide-based biomimetic matrices for advanced wound care and surgical reconstruction. Its two commercial products, G4Derm Plus (a flowable biomimetic matrix for complex chronic wounds) and Suprello (a surgical wound matrix for high-risk surgical cases), are built on its proprietary Smart Materials Platform using self-assembling peptides that mimic the human extracellular matrix to support tissue regrowth while providing antibacterial protection.

Product overview

Gel4Med is a commercial-stage biomaterials company founded out of Harvard Innovation Labs, utilizing its proprietary Smart Materials Platform (SMP™) — a patented bioengineering technology based on self-assembling peptides — to develop and commercialize therapeutic biomaterials for wound care, surgical reconstruction, and regenerative medicine. The company's product portfolio consists of two FDA 510(k)-cleared products: G4Derm™ Plus (a flowable biomimetic matrix for managing complex wounds, including diabetic ulcers, pressure ulcers, venous/arterial/mixed-etiology lower extremity ulcers, surgical wounds, and partial-thickness burns) and Suprello™ (a peptide-based surgical wound matrix targeting high-risk surgical cases with antibacterial protection). Both products are built on the SMP™ technology and delivered via prefilled syringes with applicator tips. The company also maintains an active pipeline including a spinal cord injury cell therapy candidate being developed in collaboration with the University of Miami's Miami Project to Cure Paralysis.

Differentiator

Problem solved

Functional benefit

Brands

• Smart Materials Platform (SMP): Proprietary bioengineering platform using self-assembling peptides for developing therapeutics and devices for clinical needs.
• G4Derm Plus
• Suprello

Products and services

• G4Derm Plus Biomimetic Matrix A flowable biomimetic matrix derived from Gel4Med's Smart Materials Platform (SMP), delivered via a prefilled syringe with flexible applicator tip for precise wound coverage. Forms a 3D scaffold mimicking human extracellular matrix (ECM) providing simultaneous tissue regrowth support and antibacterial bioburden protection. FDA 510(k) cleared for partial- and full-thickness wounds, diabetic ulcers, venous/arterial/mixed-etiology lower extremity ulcers, surgical wounds, and partial-thickness burns.
• Suprello Surgical Wound Matrix A next-generation, peptide-based surgical wound matrix engineered for high-risk surgical cases. Provides a resorbable scaffold supporting tissue regrowth and capillary growth, offers broad-spectrum antibacterial protection against multidrug-resistant organisms (MDROs) via cationic peptides, and conforms to incision margins to support wound closure. FDA 510(k) cleared, available as a 2-mL pre-filled syringe with applicator tip, covering 20 cm² of wound area.

Quantifiable outcome

• In swine full-thickness incisional wound model, Suprello achieved complete tissue apposition and full closure (100% re-epithelialization) of MRSA-infected wounds with complete material resorption by Day 7 post-op
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

13 partnerships are on record, tiered core and minor.

• Summit Products Group and MiMEDX Group, Inc.coreChannel Partner/ Reseller/ Distributor · 9 February 2026Distribution collaboration to expand acute-care and surgical-suite market access for G4Derm Plus Biomimetic Matrix. Summit Products Group distributes G4Derm Plus alongside MiMEDX's portfolio of surgical and wound care products, leveraging MiMEDX's established GPO and IDN contracting capabilities to accelerate hospital-system adoption.
• Centers for Medicare and Medicaid Services (CMS)coreOthers · 28 August 2025CMS assigned unique Healthcare Common Procedure Coding System (HCPCS) Level II code A2037 to G4Derm Plus, enabling standardized billing and insurance coverage for the product.
• Spartan MedicalcoreChannel Partner/ Reseller/ Distributor · 2 July 2025Partnership to supply G4Derm Plus and Suprello to VA and DoD medical facilities nationwide. Spartan Medical is a trusted leader in medical solutions to Veterans Affairs Medical Centers and Department of Defense Military Treatment Facilities.
• University of Miami's Miami Project to Cure ParalysiscoreStrategic or Co-development Partner · 1 May 2024Collaboration on study funded by Department of Defense to explore novel cell therapy approach for spinal cord injuries using Gel4Med's Smart Materials Platform to deliver Schwann cells. Research aims to develop treatment leading to human clinical trials and potential new drug application.
• Massachusetts General Hospital / Harvard Medical SchoolcoreStrategic or Co-development PartnerClinical collaborators who published real-world evidence case series on G4Derm Plus biomimetic matrix, highlighting rapid healing of diabetic foot ulcers refractory to advanced wound treatments.
• Georgetown UniversityminorStrategic or Co-development PartnerAcademic medical center collaborator listed on G4Derm Plus product page.
• University of Texas Southwestern Medical CenterminorStrategic or Co-development PartnerDr. Paul Kim, Medical Director, serves as key opinion leader for G4Derm Plus in lower extremity wound care.
• Wake Forest UniversityminorStrategic or Co-development PartnerAcademic medical center collaborator listed on G4Derm Plus product page.
• Mount Sinai Health SystemminorStrategic or Co-development PartnerAcademic medical center collaborator listed on G4Derm Plus product page.
• Jefferson HealthminorStrategic or Co-development PartnerAcademic medical center collaborator listed on G4Derm Plus product page.
• Miller School Of Medicine (University of Miami)minorStrategic or Co-development PartnerAcademic collaborator partner shown in platform page pipeline section.
• University of DelawareminorStrategic or Co-development PartnerAcademic collaborator partner with Dr. Darrin Poachan (Chair Of Dept. of Materials Science & Engineering) serving on Gel4Med Advisory Board.
• Harvard UniversityminorStrategic or Co-development PartnerFounding institution from Harvard Innovation Labs; listed as collaborator on platform page.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• MiMEDX Group: Public regenerative medicine company (Nasdaq: MDXG) selling placental/amniotic tissue allografts (EpiFix, AmnioFix) for wound care and surgical recovery. Closest direct peer because it competes in the same skin-substitute/wound-care category and is simultaneously Gel4Med's distribution partner via Summit Products Group.
• Integra LifeSciences: Public medical device company (Nasdaq: IART) with a regenerative tissue technologies franchise including Integra Dermal Regeneration Template and other wound/surgical matrices. Directly comparable to Gel4Med's biomimetic matrix strategy, and a member of Gel4Med's advisory board (former CSO Kenneth Burhop) reinforces industry linkage.
• Organogenesis: Public regenerative medicine company (Nasdaq: ORGO) selling living-cell skin substitutes (Apligraf, Dermagraft) and amniotic products (PuraPly, NuShield) for chronic and surgical wound care. Directly competes in advanced wound care with overlapping indications including diabetic foot ulcers and venous leg ulcers.

Emerging players

• PolyNovo: ASX-listed biomaterials company developing synthetic, biodegradable dermal matrices (NovoSorb BTM) for burns and complex wound management. Closely comparable to Gel4Med's synthetic, peptide-based biomimetic matrix approach and is similarly sized but already commercializing internationally.
• Vericel: Public regenerative medicine company (Nasdaq: VCEL) marketing autologous cell therapies (MACI for cartilage repair, Epicel for burns). Comparable as a small-cap commercial regenerative-medicine peer pursuing hospital and specialty surgical channels with novel biologic/biomaterial therapies.
• Anika Therapeutics: Public regenerative medicine company (Nasdaq: ANIK) with hyaluronic-acid-based products for orthopedics, pain management, and surgical tissue repair. Comparable as a small-cap, commercial-stage regenerative-medicine peer working with surgeons and hospitals on tissue-healing applications.

Broad incumbents

• Smith & Nephew: Large global medical device company (NYSE: SNN) with a leading Advanced Wound Management portfolio (ALLEVYN, PICO, OASIS) covering dressings, NPWT, and skin substitutes. Sets the competitive baseline in advanced wound care that Gel4Med must displace in hospital and clinic accounts.
• ConvaTec: Public wound care and ostomy specialist (LSE: CTEC) with products such as AQUACEL, Foam Lite, and InnovaMatrix for advanced and surgical wound care. Broad incumbent competing across overlapping wound-care indications targeted by G4Derm Plus and Suprello.
• Coloplast: Danish-listed global leader (CPH: COLO-B) in ostomy, continence, and wound care, including the Biatain and Convatec-comparable advanced wound dressings portfolio. Represents one of the largest established players in chronic and surgical wound management globally.
• Mölnlycke Health Care: Privately held Swedish wound care and surgical solutions company with Mepilex, Mepitel, and Avance negative-pressure wound therapy. Competes broadly across hospital and surgical wound care, including advanced foam and antimicrobial dressings adjacent to G4Derm Plus's positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/gelformed

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds7 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gel4Med